This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (13)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Glaucoma  • Articles for Residents  • Alert me on articles by topic

The Mainz 1 Study

N. Pfeiffer, MD; I. Grierson, PhD; H. Goldsmith, BSc; D. Hochgesand, MD; A. Winkgen-Böhres, MD; P. Appleton, PhD

Arch Ophthalmol. 2001;119:191-196.

Objective  To determine whether 3 months of topical latanoprost treatment caused proliferative or degenerative effects on the peripheral iris of patients with glaucoma.

Methods  Seventeen patients requiring filtering surgery for primary open-angle glaucoma or pseudoexfoliation glaucoma were randomized to receive topical latanoprost for 3 months (n = 8) or alternative medication (n = 9) before surgery. A trabeculectomy and a peripheral iridectomy specimen was obtained from each patient during surgery. The tissue was subjected to histological and immunohistochemical evaluation using 2 cell cycle markers: proliferating cell nuclear antigen and nuclear-associated protein (Ki-67).

Results  No degenerative or pathological changes were seen in the latanoprost-treated irides, including the one specimen in this series in which there was an eye color change. Proliferating cell nuclear antigen and nuclear-associated protein markers were negative for changes in all the test specimens.

Conclusion  Short-term treatment with latanoprost does not produce morphological changes or cellular proliferation changes in the iris.

From the Department of Ophthalmology, Mainz University, Mainz, Germany (Drs Pfeiffer, Hochgesand, and Winkgen-Böhres); and the Unit of Ophthalmology, University of Liverpool, Liverpool, England (Drs Grierson and Appleton and Ms Goldsmith).

RELATED ARTICLE

Archives of Ophthalmology Reader's Choice: Continuing Medical Education
Arch Ophthalmol. 2001;119(2):315-316.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

A Study of Histopathological Features of Latanoprost-Treated Irides With or Without Darkening Compared With Non-Latanoprost-Treated Irides
Albert et al.
Arch Ophthalmol 2008;126:626-631.
ABSTRACT | FULL TEXT  

Bimatoprost-Induced Periocular Skin Hyperpigmentation: Histopathological Study
Kapur et al.
Arch Ophthalmol 2005;123:1541-1546.
ABSTRACT | FULL TEXT  

A Study of Iridectomy Histopathologic Features of Latanoprost- and Non-Latanoprost-Treated Patients
Albert et al.
Arch Ophthalmol 2004;122:1680-1685.
ABSTRACT | FULL TEXT  

A 5-Year, Multicenter, Open-Label, Safety Study of Adjunctive Latanoprost Therapy for Glaucoma
Alm et al.
Arch Ophthalmol 2004;122:957-965.
ABSTRACT | FULL TEXT  

New topical drugs for open-angle glaucoma
DTB 2003;41:12-14.
ABSTRACT | FULL TEXT  

Fine Structural Evaluation of the Iris After Unilateral Treatment With Latanoprost in Patients Undergoing Bilateral Trabeculectomy (The Mainz II Study)
Pfeiffer et al.
Arch Ophthalmol 2003;121:23-31.
ABSTRACT | FULL TEXT